Immix Biopharma, Inc. announced that 14 U.S. sites are actively enrolling in U.S. multi-site study NEXICART-2. This milestone adds 10 sites since the Company's most recent update. The company anticipates completing NEXICART-2 clinical trial ahead of schedule. Phase 1/2 interim readout data from its U.S. NXC-201 NEXICART-2 trial in relapsed/refractory AL Amyloidosis has been selected for oral presentation at the upcoming 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) being held in Chicago, Illinois, May 30 - June 3, 2025, presented by lead investigator Heather Landau, M.D., Director of Amyloidosis Program and a Bone Marrow Transplant Specialist & Cellular Therapist at Memorial Sloan-Kettering Cancer Center in New York.
NEXICART-2 (NCT06097832) is an ongoing single-arm multi-site U.S. Phase 1/2 clinical trial of clinically-optimized CAR-T NXC-201 in relapsed/refractories AL Amyloidosis. NEXICART- 2 is expected to enroll 40 patients with preserved heart function (excluding patients with pre-existing heart failure) who have not been exposed to prior BCMA-targeted therapy. Initial data from ex-U.S. study NEXICART-1 has demonstrated high complete response rates in relapsed/refractORY AL Amyloidosis.XC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA, and Orphan Drug Designation (ODD) by the US FDA and in the EU by the EMA.
